The company Walmark has fulfilled the requirements of the Drug Act and the GMP Decree for the Manufacture and Distribution of Pharmaceuticals in the Czech Republic and has proven the functionality of the established GMP (Good Manufacturing Practice) system.
Good Manufacturing Practice is a set of rules which are binding for pharmaceutical companies. A pharmaceutical company must ensure that the course of manufacture and all connected processes take place according to these rules which guarantee the manufacture of top quality, effective and safe pharmaceuticals.
Walmark has been the holder of a permit for the manufacture of pharmaceuticals since 2003. Walmark has been regularly investing a significant amount of money to new production and development technologies, control system and extension of the existing quality control mechanisms.
Recently the manufacturing plant has been extended by a fluid granulation mechanism. It is a new technology for the manufacturing of tablets that contributes to the possibility of manufacturing tablets which are technologically more exacting, raw materials savings and the increase of the quality of the existing tablets on the basis of a better homogeneity of the mixture.
Production in the Walmark company takes place in compliance with all the legislative requirements that are placed on the individual types of manufactured products; this concerns in particular the Food Act, the Drug Act and other related decrees by the Ministry of Health of the Czech Republic and the State Institute for Pharmaceutical Control. The company is inspected by the responsible state authorities - Czech Agricultural and Food Inspection and State Institute for Pharmaceutical
Control (SÚKL).